PLEASANTON, Calif.--(BUSINESS WIRE)--10x Genomics, a company focused on improving and broadening the application of genomic information, today announced the launch and release of the new Chromium™ Single Cell Controller, a massively scalable tool for comprehensive single cell analysis. The new system and applications will be unveiled at the 2016 American Society of Human Genetics (ASHG) Annual Meeting being held October 18 – 22 in Vancouver, Canada.
The Chromium Single Cell Controller is a dedicated instrument for single cell applications and features a simple and comprehensive workflow, enabling users to quickly and easily prepare single cell sequencing libraries in less than one workday. With the unique ability to interrogate hundreds to millions of cells, the Single Cell Chromium Controller supports a variety of applications, including the existing Chromium™ Single Cell 3’ Solution for single cell transcriptomics, as well as a potential future product featuring the ability to perform full-length sequencing of paired expressed V(D)J segments from single B or T cells. The system is accompanied by Chromium Single Cell 3’ Reagent Kits with advanced chemistry and microfluidics consumables based on GemCode™ Technology and features full compatibility with the Illumina® HiSeq® 4000 and other HiSeq®, NextSeq® and MiSeq® sequencers.
The comprehensive solution includes a complete, easy-to-use software suite for rapid analysis and visualization of very large single cell datasets. The Cell Ranger™ pipeline leverages barcoding to perform gene expression analysis with single cell resolution at million cell scale. The Loupe™ for Cells visualization application features powerful but easy-to-use clustering and differential expression analysis for the output of the Cell Ranger pipeline. A new, enhanced release of Cell Ranger, and the first release of Loupe for Cells, will be available by the end of 2016.
“10x is expanding our applications portfolio to address the need for better tools in the growing field of immuno-oncology," said Serge Saxonov, co-founder and chief executive officer of 10x Genomics. “As such, we have designed our new dedicated single cell solution to be practical and accessible to individual laboratories engaged in early-stage discovery and translational research, while also continuing to provide the massive-scalability needed for more complex cell and tissue atlas projects.”
The Chromium™ Single Cell Controller is currently available with a U.S. introductory price of $50,000 (introductory price available until December 31, 2016).
The company will be presenting data from the Chromium™ Single Cell 3’ Solution and Controller during a workshop and oral presentation at ASHG 2016.
“Transforming Genomic Analysis with the 10x Chromium System”
Presenters: Tarjei Mikkelsen, Ph.D., single cell core team leader, 10x Genomics; Calvin Kuo, M.D. Ph.D., professor of chemical and systems biology, Stanford University; and Chris Whelan, Ph.D., computational biologist, Broad Institute
Date, Time: Friday, October 21 from 1:00 p.m. – 2:30 p.m. PT
Location: Room 2/3, East Building
Oral Presentation #292:
“Massively parallel digital transcriptional profiling of single cells.”
Presenting Author: Grace X.Y. Zheng, Ph.D., senior scientist, 10x Genomics
Date, Time: Saturday, October 22 from 11:15 a.m. – 11:30 a.m. PT
Location: Ballroom B
More information on the Chromium Single Cell Controller can found at:
Chromium Single Cell datasets are available for download at:
About 10x Genomics
10x Genomics is changing the definition of sequencing by providing an innovative genomics platform that dramatically upgrades the capabilities of existing sequencing technologies. This is achieved through a combination of new microfluidic science, chemistry and bioinformatics. By implementing GemCodeTM Technology within the Chromium System, researchers can now, for the first time, find new structural variants, haplotypes and other valuable genomic information with comprehensive workflows for Single Cell, Genome, Exome and De Novo Assembly applications that incorporate their pre-existing sequencing technologies.